Olmesartan Medoxomilo + Hidroclorotiazida Farmoz (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil combined with hydrochlorothiazide is used to manage high blood pressure by targeting the renin‑angiotensin‑aldosterone system.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure prevention: assists in controlling blood pressure to lessen workload on the heart.
• Chronic kidney disease: helps slow progression by managing hypertension in patients with renal impairment.

• Olmesartan medoxil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, promoting diuresis and further reducing plasma volume. The combined actions produce additive blood‑pressure‑lowering effects.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Dizziness
• Headache
• Fatigue
• Increased urination
• Electrolyte imbalance (low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Liver function abnormalities
• Blood cell disorders (e.g., agranulocytosis).

Patients should be evaluated for contraindications and monitored throughout treatment.

• Renal impairment: adjust dose and monitor kidney function.
• Hepatic disease: use with caution; monitor liver enzymes.
• Electrolyte disturbances: check serum potassium and sodium regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Elderly patients: start at lower dose and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Olmesartan medoxil + Hydrochlorothide may interact with several drug classes.

Major Interactions (Avoid)

• Potassium‑rich supplements or potassium‑sparing diuretics: risk of hyperkalemia.
• Aliskiren (in diabetic patients): increased risk of renal dysfunction.
• NSAIDs (high‑dose): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: may increase serum lithium levels.
• Antifungal azoles (e.g., ketoconazole): can raise olmesartan concentrations.
• Beta‑blockers: additive blood‑pressure lowering effect.
• ACE inhibitors: combined use may increase risk of renal impairment and hyperkalemia.